CRISPR-Cas9 MPO knockout shuts down oxidative neutrophil chemistry without crippling core defenses
Engineered deletion of myeloperoxidase in human hematopoietic stem and progenitor cells produced neutrophils that kept most of their basic antimicrobial machinery intact while losing two MPO-linked inflammatory functions: chlorination and PMA-induced neutrophil extracellular trap release. The work positions MPO as a selective target rather than a blunt one. In this stem cell editing model, the cells still handled phagocytosis, superoxide generation, and key degranulation programs, which matters because those pathways sit at the center of neutrophil host defense.
The finding carries a clear biological logic. MPO sits downstream of NADPH oxidase and converts hydrogen peroxide into highly reactive chlorinating species such as hypochlorous acid, a chemistry class that is useful against pathogens but also capable of collateral tissue injury. By removing MPO at the level of the hematopoietic stem cell, the investigators aimed to cut off that oxidative arm before it reaches mature neutrophils. The result was a cell population with a sharply altered inflammatory chemistry profile rather than a broadly disabled innate immune phenotype.
Why MPO has become an attractive target in inflammatory disease
MPO is not a niche enzyme. It is a major neutrophil heme peroxidase and is implicated in a wide range of inflammatory disorders, including atherosclerosis, autoimmune disease, obesity-related inflammation, liver disease, arthritis, neurodegenerative disease, and cancer. Its abundance in activated neutrophils and its position in the oxidative burst make it a plausible contributor to bystander injury in tissues where neutrophils accumulate. When oxidative products spill beyond the phagolysosome, they can injure endothelium, extracellular matrix, and parenchymal cells even while the immune system is trying to clear a threat.
Inherited MPO deficiency has long suggested that the enzyme is not essential for survival in the way many core immune pathways are. Most people with complete or partial deficiency do not show an obvious increase in bacterial, fungal, or viral infections, and some cohorts have even shown lower cardiovascular disease rates. That combination of apparent clinical tolerance and potential protection from inflammatory damage has made MPO an appealing pharmacologic target. Yet small-molecule inhibitors have not solved the problem cleanly, in part because blocking extracellular enzyme activity alone may not extinguish the full MPO-driven pathway.
Stem cell editing created a durable MPO-deficient neutrophil model
To test whether a permanent genetic strategy could do better, the investigators used CRISPR-Cas9 to edit human hematopoietic stem and progenitor cells and then differentiated those cells into neutrophils in vitro. A RAG2 knockout served as the edited control, allowing the team to separate effects from the CRISPR-electroporation procedure itself from effects specific to MPO loss. Unedited mock cells provided the baseline for normal differentiation and function.
The design matters because hematopoietic stem cells are self-renewing. A successful edit at this stage offers the possibility of continuous production of altered myeloid cells rather than a transient pharmacologic interruption. For diseases in which neutrophil-mediated oxidative injury persists over months or years, that durability could be clinically relevant if the approach proves safe in vivo. The study stayed focused on function, not therapeutic claims, and that restraint is appropriate.
Core neutrophil functions survived the knockout
Across the assay panel, MPO-KO neutrophils did not show major losses in the non-oxidative functions tested. Neutrophil elastase activity remained intact, as did fMLP-induced neutrophil elastase and MMP9 degranulation. Phagocytosis of E. coli and S. aureus bioparticles was preserved. Superoxide production also remained measurable, which is important because it places the defect downstream of the upstream oxidase machinery rather than at the level of general reactive oxygen species generation.
One sentence captures the central signal: the knockout removed MPO-dependent chemistry without erasing the neutrophil’s basic operational toolkit.
That pattern is exactly what makes MPO attractive as a precision target. Neutrophils still formed superoxide through the NADPH oxidase pathway, still mobilized granule enzymes, and still engulfed microbial particles. What disappeared was the enzyme’s chlorinating output, the branch of oxidative biology most associated with downstream collateral injury.
Chlorination vanished and PMA-driven NET formation dropped sharply
The most decisive changes appeared where MPO is known to be indispensable. MPO-dependent chlorination was abolished in the knockout cells, which is expected if the enzyme itself is absent. PMA-induced neutrophil extracellular trap release was also profoundly reduced. Because NET formation depends on a complex oxidative program and has been linked to MPO in prior work, the drop is biologically coherent and reinforces MPO’s position as more than a passive bystander in neutrophil activation.
NET biology sits at an uneasy crossroads in inflammation. NETs can help immobilize pathogens, but excessive or misplaced NET formation can drive endothelial damage, thrombosis, and persistent tissue inflammation. In settings such as atherosclerosis and autoimmune disease, those structures can become part of the pathology they were meant to contain. A genetic approach that blunts MPO-linked NET release while preserving phagocytosis could, in theory, separate useful antimicrobial activity from the more destructive extracellular consequences of neutrophil activation.
What the RAG2 control clarified about the editing platform
The edited control added an important layer of internal validity. RAG2 knockout cells retained the measured neutrophil functions, supporting the conclusion that the observed phenotype was tied to MPO loss rather than to the genome-editing process itself. In a platform study like this, that distinction is essential. Stem cell editing can introduce stress responses, and control design has to rule out the possibility that the biology being measured is simply an electroporation artifact.
The methods also show a technically careful approach to validation. Editing efficiency was assessed by PCR amplification and Sanger sequencing with ICE analysis, while differentiation and functional testing were carried out during a defined window in the later stages of culture. Flow cytometry, enzymatic assays, chemiluminescence measurements, and bacterial particle phagocytosis collectively built a broad phenotype map instead of relying on one readout. That breadth helps distinguish selective MPO loss from generalized neutrophil failure.
Translating MPO editing into disease models remains the next test
The study stops short of claiming clinical utility, and that boundary should remain in place. These are in vitro differentiated neutrophils generated from edited human stem cells, not patients, not tissues, and not disease models with ongoing inflammation. The most immediate question is whether the same selective loss of chlorination and NET formation would translate into a meaningful reduction in tissue injury in vivo without creating new vulnerabilities under infectious pressure.
Future work will need to test whether stem cell-level MPO deletion can blunt pathogenic inflammation in relevant models of cardiovascular, autoimmune, or other MPO-associated disease. It will also need to establish how complete the protection is across different neutrophil activation pathways, because PMA is only one trigger and inflammatory disease does not present a single stimulus. The central unanswered issue is not whether MPO can be removed from human neutrophils. It is whether this kind of editing can suppress the harmful arm of neutrophil biology while preserving enough host defense to make the strategy safe in the body.